Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2) (INSPiRE-ICU2)
Primary Purpose
Sedation
Status
Recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Isoflurane
Propofol
Sponsored by

About this trial
This is an interventional treatment trial for Sedation focused on measuring sedation, mechanical ventilation, propofol, ICU, isoflurane
Eligibility Criteria
Inclusion Criteria:
- Adults ≥18 years of age;
- Patients who are anticipated to require >12 hours of invasive mechanical ventilation and continuous sedation in the ICU; and
- Receipt of continuous sedation due to clinical need for sedation to RASS <0.
Exclusion Criteria:
- Need for RASS -5;
- Sedation for invasive mechanical ventilation immediately prior to Baseline for >72 hours;
- Severe neurological condition before ICU admission that causes the patient to lack ability to participate in the study (ie, unable to be assessed for RASS and CPOT);
- Ventilator tidal volume <200 or >1000 mL at Baseline;
- Need for extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2R), high frequency oscillation ventilation (HFOV), or high frequency percussive ventilation (HFPV) at Screening;
- Comfort care only (end of life care);
- Contraindication to propofol or isoflurane;
- Known or family history of MH;
- Severe hemodynamic compromise, defined as the need for norepinephrine ≥0.3 mcg/kg/min (or equivalent vasopressor dose) to maintain blood pressure within acceptable range, assumed to be mean arterial pressure ≥65 mmHg unless prescribed clinically;
- Allergy to isoflurane or propofol, or have propofol infusion syndrome.
- History of ventricular tachycardia/Long QT Syndrome;
- Requirement of IV benzodiazepine or barbiturate administration for seizures or dependencies, including alcohol withdrawal
- Neuromuscular disease that impairs spontaneous ventilation (eg, C5 or higher spinal cord injury, amyotrophic lateral sclerosis, etc);
- Concurrent enrollment in another study that, in the Investigator's opinion, would impact the patient's safety or assessments of this study;
- Participation in other study involving investigational drug(s) or devices(s) within 30 days prior to Randomization;
- Anticipated requirement of treatment with continuous infusion of a neuromuscular blocking agent for >4 hours;
- Female patients who are pregnant or breast-feeding;
- Imperative need for continuous active humidification through mechanical ventilation circuit;
- Attending physician's refusal to include the patient; or
- Inability to obtain informed consent.
Sites / Locations
- University of California, Los AngelesRecruiting
- Stanford UniversityRecruiting
- University of California, San DiegoRecruiting
- Rush University Medical CenterRecruiting
- Massachusetts General HospitalRecruiting
- Beth Israel Deaconess Medical CenterRecruiting
- University of MichiganRecruiting
- The New York and Presbyterian HospitalRecruiting
- Ohio State UniversityRecruiting
- Thomas Jefferson University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Isoflurane
Propofol
Arm Description
Inhaled isoflurane administered via Sedaconda ACD-S
Propofol administered as intravenous infusion
Outcomes
Primary Outcome Measures
Percentage of time adequate sedation depth
To compare the percentage of time sedation depth is maintained within the target range, in absence of rescue sedation, as assessed according to the RASS scale, in isoflurane- vs propofol-treated patients
Secondary Outcome Measures
Key Secondary: Compare the use of opioids
To compare the effect of isoflurane vs propofol on use of opioids during the study drug treatment period measuring CPOT
Key Secondary: Compare the wake up time
To compare the effect of isoflurane vs propofol on the wake up time at end of study drug treatment
Key Secondary: Compare the cognitive recovery after EOT
To compare the effect of isoflurane vs propofol on cognitive recovery after EOT by measuring CAM-ICU-7
Key Secondary: Compare the spontaneous breathing effort
To compare the effect of isoflurane vs propofol on spontaneous breathing effort during the study drug treatment period by measuring
• Airway occlusion pressure, pressure support or if observed respiratory rate exceeds set respiratory rate
Other secondary: Compare time from sedation termination to extubation
To compare the effect of isoflurane vs propofol on time from sedation termination to extubation in patients for whom study drug is terminated for extubation
Other secondary: Compare days alive and free of mechanical ventilation through Study Day 30
To compare the effect of isoflurane vs propofol on days alive and free of mechanical ventilation through Study Day 30
Other secondary: Compare days alive and free of the ICU
To compare the effect of isoflurane vs propofol on days alive and free of the ICU
Other secondary: Compare delirium and coma free days until 7 days after EOT
To compare the effect of isoflurane vs propofol on delirium and coma free days until 7 days after EOT
Other secondary: Compare mortality at 30 days after randomization
To compare the effect of isoflurane vs propofol on mortality at 30 days after randomization
Other secondary: Compare mortality at 3 months after randomization
To compare the effect of isoflurane vs propofol on mortality at 3 months after randomization
Other secondary: Compare mortality at 6 months after randomization
To compare the effect of isoflurane vs propofol on mortality at 6 months after randomization
Other secondary: To compare the safety profile of isoflurane vs propofol
To compare the safety profile of isoflurane vs propofol in respect to reported Adverse Event
Other secondary: To assess Sedaconda ACD-S device deficiencies in patients receiving isoflurane
To assess Sedaconda ACD-S device deficiencies in patients receiving isoflurane by Sedaconda ACD-S by reported Adverse Event
Other secondary: To compare the use of restraints in patients receiving isoflurane vs propofol
Incidence of restraints measured twice daily
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05327296
Brief Title
Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)
Acronym
INSPiRE-ICU2
Official Title
A Phase 3, Multicenter, Randomized, Controlled, Open Label, Assessor-Blinded Study to Evaluate the Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 30, 2022 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sedana Medical
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a study to compare safety and efficacy of inhaled isoflurane administered via the Sedaconda ACD-S device system versus intravenous propofol for sedation of mechanically ventilated patients in the Intensive Care Unit (ICU) setting.
Detailed Description
This is a phase 3, multicenter, randomized, controlled, open-label, assessor-blinded study to evaluate the efficacy and safety of inhaled isoflurane delivered via the Sedaconda ACD-S compared to intravenous propofol for sedation of mechanically ventilated Intensive Care Unit (ICU) adult patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sedation
Keywords
sedation, mechanical ventilation, propofol, ICU, isoflurane
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
235 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Isoflurane
Arm Type
Experimental
Arm Description
Inhaled isoflurane administered via Sedaconda ACD-S
Arm Title
Propofol
Arm Type
Active Comparator
Arm Description
Propofol administered as intravenous infusion
Intervention Type
Drug
Intervention Name(s)
Isoflurane
Intervention Description
Inhaled isoflurane administered by Sedaconda ACD-S
Intervention Type
Drug
Intervention Name(s)
Propofol
Intervention Description
Intravenous infusion of propofol
Primary Outcome Measure Information:
Title
Percentage of time adequate sedation depth
Description
To compare the percentage of time sedation depth is maintained within the target range, in absence of rescue sedation, as assessed according to the RASS scale, in isoflurane- vs propofol-treated patients
Time Frame
During study treatment up to 48 (±6) hours
Secondary Outcome Measure Information:
Title
Key Secondary: Compare the use of opioids
Description
To compare the effect of isoflurane vs propofol on use of opioids during the study drug treatment period measuring CPOT
Time Frame
During study treatment up to 48 (±6) hours
Title
Key Secondary: Compare the wake up time
Description
To compare the effect of isoflurane vs propofol on the wake up time at end of study drug treatment
Time Frame
Time from stop of study drug treatment up to 4 hours
Title
Key Secondary: Compare the cognitive recovery after EOT
Description
To compare the effect of isoflurane vs propofol on cognitive recovery after EOT by measuring CAM-ICU-7
Time Frame
60 minutes after EOT
Title
Key Secondary: Compare the spontaneous breathing effort
Description
To compare the effect of isoflurane vs propofol on spontaneous breathing effort during the study drug treatment period by measuring
• Airway occlusion pressure, pressure support or if observed respiratory rate exceeds set respiratory rate
Time Frame
During study treatment up to 48 (±6) hours
Title
Other secondary: Compare time from sedation termination to extubation
Description
To compare the effect of isoflurane vs propofol on time from sedation termination to extubation in patients for whom study drug is terminated for extubation
Time Frame
During study treatment
Title
Other secondary: Compare days alive and free of mechanical ventilation through Study Day 30
Description
To compare the effect of isoflurane vs propofol on days alive and free of mechanical ventilation through Study Day 30
Time Frame
From start of study treatment up to 30 days
Title
Other secondary: Compare days alive and free of the ICU
Description
To compare the effect of isoflurane vs propofol on days alive and free of the ICU
Time Frame
From start of study treatment up to 30 days
Title
Other secondary: Compare delirium and coma free days until 7 days after EOT
Description
To compare the effect of isoflurane vs propofol on delirium and coma free days until 7 days after EOT
Time Frame
From start of study treatment until 7 days after EOT
Title
Other secondary: Compare mortality at 30 days after randomization
Description
To compare the effect of isoflurane vs propofol on mortality at 30 days after randomization
Time Frame
Until 30 days after randomization
Title
Other secondary: Compare mortality at 3 months after randomization
Description
To compare the effect of isoflurane vs propofol on mortality at 3 months after randomization
Time Frame
Until 3 months after randomization
Title
Other secondary: Compare mortality at 6 months after randomization
Description
To compare the effect of isoflurane vs propofol on mortality at 6 months after randomization
Time Frame
Until 6 months after randomization
Title
Other secondary: To compare the safety profile of isoflurane vs propofol
Description
To compare the safety profile of isoflurane vs propofol in respect to reported Adverse Event
Time Frame
Baseline to end of study treatment, safety lab from baseline up to 48hrs post treatment, AEs from start study treatment up to day 30
Title
Other secondary: To assess Sedaconda ACD-S device deficiencies in patients receiving isoflurane
Description
To assess Sedaconda ACD-S device deficiencies in patients receiving isoflurane by Sedaconda ACD-S by reported Adverse Event
Time Frame
During study treatment up to 48 (±6) hours
Title
Other secondary: To compare the use of restraints in patients receiving isoflurane vs propofol
Description
Incidence of restraints measured twice daily
Time Frame
During study treatment up to 48 (±6) hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults ≥18 years of age;
Patients who are anticipated to require >12 hours of invasive mechanical ventilation and continuous sedation in the ICU; and
Receipt of continuous sedation due to clinical need for sedation to RASS <0.
Exclusion Criteria:
Need for RASS -5;
Sedation for invasive mechanical ventilation immediately prior to Baseline for >72 hours;
Severe neurological condition before ICU admission that causes the patient to lack ability to participate in the study (ie, unable to be assessed for RASS and CPOT);
Ventilator tidal volume <200 or >1000 mL at Baseline;
Need for extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2R), high frequency oscillation ventilation (HFOV), or high frequency percussive ventilation (HFPV) at Screening;
Comfort care only (end of life care);
Contraindication to propofol or isoflurane;
Known or family history of MH;
Severe hemodynamic compromise, defined as the need for norepinephrine ≥0.3 mcg/kg/min (or equivalent vasopressor dose) to maintain blood pressure within acceptable range, assumed to be mean arterial pressure ≥65 mmHg unless prescribed clinically;
Allergy to isoflurane or propofol, or have propofol infusion syndrome.
History of ventricular tachycardia/Long QT Syndrome;
Requirement of IV benzodiazepine or barbiturate administration for seizures or dependencies, including alcohol withdrawal
Neuromuscular disease that impairs spontaneous ventilation (eg, C5 or higher spinal cord injury, amyotrophic lateral sclerosis, etc);
Concurrent enrollment in another study that, in the Investigator's opinion, would impact the patient's safety or assessments of this study;
Participation in other study involving investigational drug(s) or devices(s) within 30 days prior to Randomization;
Anticipated requirement of treatment with continuous infusion of a neuromuscular blocking agent for >4 hours;
Female patients who are pregnant or breast-feeding;
Imperative need for continuous active humidification through mechanical ventilation circuit;
Attending physician's refusal to include the patient; or
Inability to obtain informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Magnus Falkenhav, M.D.
Phone
+46 70 856 1687
Email
magnus.falkenhav@sedanamedical.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeremy Beitler, M.D.
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Individual Site Status
Recruiting
Facility Name
Stanford University
City
Redwood City
State/Province
California
ZIP/Postal Code
94063
Country
United States
Individual Site Status
Recruiting
Facility Name
University of California, San Diego
City
San Diego
State/Province
California
ZIP/Postal Code
92023
Country
United States
Individual Site Status
Recruiting
Facility Name
Rush University Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Name
The New York and Presbyterian Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Recruiting
Facility Name
Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Individual Site Status
Recruiting
Facility Name
Thomas Jefferson University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Individual Site Status
Not yet recruiting
12. IPD Sharing Statement
Citations:
PubMed Identifier
30113379
Citation
Devlin JW, Skrobik Y, Gelinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-e873. doi: 10.1097/CCM.0000000000003299.
Results Reference
background
PubMed Identifier
31112380
Citation
Shehabi Y, Howe BD, Bellomo R, Arabi YM, Bailey M, Bass FE, Bin Kadiman S, McArthur CJ, Murray L, Reade MC, Seppelt IM, Takala J, Wise MP, Webb SA; ANZICS Clinical Trials Group and the SPICE III Investigators. Early Sedation with Dexmedetomidine in Critically Ill Patients. N Engl J Med. 2019 Jun 27;380(26):2506-2517. doi: 10.1056/NEJMoa1904710. Epub 2019 May 19.
Results Reference
background
PubMed Identifier
10816184
Citation
Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000 May 18;342(20):1471-7. doi: 10.1056/NEJM200005183422002.
Results Reference
background
PubMed Identifier
23180503
Citation
Mehta S, Burry L, Cook D, Fergusson D, Steinberg M, Granton J, Herridge M, Ferguson N, Devlin J, Tanios M, Dodek P, Fowler R, Burns K, Jacka M, Olafson K, Skrobik Y, Hebert P, Sabri E, Meade M; SLEAP Investigators; Canadian Critical Care Trials Group. Daily sedation interruption in mechanically ventilated critically ill patients cared for with a sedation protocol: a randomized controlled trial. JAMA. 2012 Nov 21;308(19):1985-92. doi: 10.1001/jama.2012.13872. Erratum In: JAMA. 2013 Jan 16;309(3):237.
Results Reference
background
PubMed Identifier
18431266
Citation
Sackey PV, Martling CR, Carlsward C, Sundin O, Radell PJ. Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study. Crit Care Med. 2008 Mar;36(3):801-6. doi: 10.1097/CCM.0B013E3181652FEE.
Results Reference
background
PubMed Identifier
21445642
Citation
Mesnil M, Capdevila X, Bringuier S, Trine PO, Falquet Y, Charbit J, Roustan JP, Chanques G, Jaber S. Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam. Intensive Care Med. 2011 Jun;37(6):933-41. doi: 10.1007/s00134-011-2187-3. Epub 2011 Mar 29.
Results Reference
background
PubMed Identifier
34454654
Citation
Meiser A, Volk T, Wallenborn J, Guenther U, Becher T, Bracht H, Schwarzkopf K, Knafelj R, Faltlhauser A, Thal SC, Soukup J, Kellner P, Druner M, Vogelsang H, Bellgardt M, Sackey P; Sedaconda study group. Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial. Lancet Respir Med. 2021 Nov;9(11):1231-1240. doi: 10.1016/S2213-2600(21)00323-4. Epub 2021 Aug 26.
Results Reference
background
PubMed Identifier
2500195
Citation
Kong KL, Willatts SM, Prys-Roberts C. Isoflurane compared with midazolam for sedation in the intensive care unit. BMJ. 1989 May 13;298(6683):1277-80. doi: 10.1136/bmj.298.6683.1277.
Results Reference
background
PubMed Identifier
33170331
Citation
Chanques G, Constantin JM, Devlin JW, Ely EW, Fraser GL, Gelinas C, Girard TD, Guerin C, Jabaudon M, Jaber S, Mehta S, Langer T, Murray MJ, Pandharipande P, Patel B, Payen JF, Puntillo K, Rochwerg B, Shehabi Y, Strom T, Olsen HT, Kress JP. Analgesia and sedation in patients with ARDS. Intensive Care Med. 2020 Dec;46(12):2342-2356. doi: 10.1007/s00134-020-06307-9. Epub 2020 Nov 10.
Results Reference
background
PubMed Identifier
32588067
Citation
Jerath A, Ferguson ND, Cuthbertson B. Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS. Intensive Care Med. 2020 Aug;46(8):1563-1566. doi: 10.1007/s00134-020-06154-8. Epub 2020 Jun 25.
Results Reference
background
PubMed Identifier
25793760
Citation
Bellgardt M, Bomberg H, Herzog-Niescery J, Dasch B, Vogelsang H, Weber TP, Steinfort C, Uhl W, Wagenpfeil S, Volk T, Meiser A. Survival after long-term isoflurane sedation as opposed to intravenous sedation in critically ill surgical patients: Retrospective analysis. Eur J Anaesthesiol. 2016 Jan;33(1):6-13. doi: 10.1097/EJA.0000000000000252.
Results Reference
background
PubMed Identifier
33528922
Citation
Hughes CG, Mailloux PT, Devlin JW, Swan JT, Sanders RD, Anzueto A, Jackson JC, Hoskins AS, Pun BT, Orun OM, Raman R, Stollings JL, Kiehl AL, Duprey MS, Bui LN, O'Neal HR Jr, Snyder A, Gropper MA, Guntupalli KK, Stashenko GJ, Patel MB, Brummel NE, Girard TD, Dittus RS, Bernard GR, Ely EW, Pandharipande PP; MENDS2 Study Investigators. Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis. N Engl J Med. 2021 Apr 15;384(15):1424-1436. doi: 10.1056/NEJMoa2024922. Epub 2021 Feb 2.
Results Reference
background
PubMed Identifier
27941501
Citation
Krannich A, Leithner C, Engels M, Nee J, Petzinka V, Schroder T, Jorres A, Kruse J, Storm C. Isoflurane Sedation on the ICU in Cardiac Arrest Patients Treated With Targeted Temperature Management: An Observational Propensity-Matched Study. Crit Care Med. 2017 Apr;45(4):e384-e390. doi: 10.1097/CCM.0000000000002185.
Results Reference
background
PubMed Identifier
18191684
Citation
Girard TD, Kress JP, Fuchs BD, Thomason JW, Schweickert WD, Pun BT, Taichman DB, Dunn JG, Pohlman AS, Kinniry PA, Jackson JC, Canonico AE, Light RW, Shintani AK, Thompson JL, Gordon SM, Hall JB, Dittus RS, Bernard GR, Ely EW. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet. 2008 Jan 12;371(9607):126-34. doi: 10.1016/S0140-6736(08)60105-1.
Results Reference
background
PubMed Identifier
24088092
Citation
Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, Brummel NE, Hughes CG, Vasilevskis EE, Shintani AK, Moons KG, Geevarghese SK, Canonico A, Hopkins RO, Bernard GR, Dittus RS, Ely EW; BRAIN-ICU Study Investigators. Long-term cognitive impairment after critical illness. N Engl J Med. 2013 Oct 3;369(14):1306-16. doi: 10.1056/NEJMoa1301372.
Results Reference
background
Links:
URL
http://www.medicines.org.uk/emc/product/9800/smpc#gref
Description
Isoflurane 100% inhalation vapour, liquid. Summary of product characteristics. West Drayton, United Kingdon. Piramal Critical Care Ltd. Electronic medicines compendium(emc), last updated 29 October 2019. Accessed 09 September 2020.
Learn more about this trial
Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)
We'll reach out to this number within 24 hrs